NanoViricides Announces Phase II Trials for Broad-Spectrum Antiviral Nanomedicine
1 report, 1 independent
Updated Oct 6
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
NanoViricides, Inc. is a clinical stage company developing a broad-spectrum antiviral nanomedicine named NV-387. The company announced that Phase II clinical trials for NV-387 began on September 23, 2026, in the Democratic Republic of Congo. The trials are investigating the drug for the treatment of both Ebola Bundibugyo Virus Disease (EVD) and Mpox disease. The company noted that, to its knowledge, NV-387 is the only oral treatment currently in clinical trials for Ebola.
From pr-inside.com
Why it matters
The company projects a potential market size exceeding $70 billion for its nanomedicine. The trials are focused on combating viral diseases that have global pandemic potential, addressing significant unmet medical needs.
From pr-inside.com
Who's involved
- DRCLocation where the company is based and trials are underway.